BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 16858683)

  • 1. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.
    Hu S; Liu D; Tufano RP; Carson KA; Rosenbaum E; Cohen Y; Holt EH; Kiseljak-Vassiliades K; Rhoden KJ; Tolaney S; Condouris S; Tallini G; Westra WH; Umbricht CB; Zeiger MA; Califano JA; Vasko V; Xing M
    Int J Cancer; 2006 Nov; 119(10):2322-9. PubMed ID: 16858683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas.
    Porra V; Ferraro-Peyret C; Durand C; Selmi-Ruby S; Giroud H; Berger-Dutrieux N; Decaussin M; Peix JL; Bournaud C; Orgiazzi J; Borson-Chazot F; Dante R; Rousset B
    J Clin Endocrinol Metab; 2005 May; 90(5):3028-35. PubMed ID: 15687339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer.
    Guan H; Ji M; Hou P; Liu Z; Wang C; Shan Z; Teng W; Xing M
    Cancer; 2008 Jul; 113(2):247-55. PubMed ID: 18470905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
    Xing M
    Endocr Rev; 2007 Dec; 28(7):742-62. PubMed ID: 17940185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
    Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
    Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
    Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
    Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypermethylated RASSF1 and SLC5A8 promoters alongside BRAF
    Khatami F; Larijani B; Heshmat R; Nasiri S; Haddadi-Aghdam M; Teimoori-Toolabi L; Tavangar SM
    J Cell Physiol; 2020 Oct; 235(10):6954-6968. PubMed ID: 32017063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
    Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
    Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.
    Lupi C; Giannini R; Ugolini C; Proietti A; Berti P; Minuto M; Materazzi G; Elisei R; Santoro M; Miccoli P; Basolo F
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4085-90. PubMed ID: 17785355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer.
    Wang Y; Ji M; Wang W; Miao Z; Hou P; Chen X; Xu F; Zhu G; Sun X; Li Y; Condouris S; Liu D; Yan S; Pan J; Xing M
    Endocr Relat Cancer; 2008 Mar; 15(1):183-90. PubMed ID: 18310286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
    Feng C; Gao Y; Wang C; Yu X; Zhang W; Guan H; Shan Z; Teng W
    J Clin Endocrinol Metab; 2013 Sep; 98(9):E1524-33. PubMed ID: 23846818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological roles of alterations of tumor suppressor gene p16 in papillary thyroid carcinoma.
    Lam AK; Lo CY; Leung P; Lang BH; Chan WF; Luk JM
    Ann Surg Oncol; 2007 May; 14(5):1772-9. PubMed ID: 17195959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma.
    Yin DT; Xu J; Lei M; Li H; Wang Y; Liu Z; Zhou Y; Xing M
    Oncotarget; 2016 Feb; 7(5):5830-41. PubMed ID: 26716505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene methylation in thyroid tumorigenesis.
    Xing M
    Endocrinology; 2007 Mar; 148(3):948-53. PubMed ID: 16946009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA methylation of MAPK signal-inhibiting genes in papillary thyroid carcinoma.
    Lee EK; Chung KW; Yang SK; Park MJ; Min HS; Kim SW; Kang HS
    Anticancer Res; 2013 Nov; 33(11):4833-9. PubMed ID: 24222120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool panel for early detection of thyroid cancer.
    Zane M; Agostini M; Enzo MV; Casal Ide E; Del Bianco P; Torresan F; Merante Boschin I; Pennelli G; Saccani A; Rubello D; Nitti D; Pelizzo MR
    Biomed Pharmacother; 2013 Oct; 67(8):723-30. PubMed ID: 23931930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].
    Yang X; Liang ZY; Meng C; Liang J; Yu Z; Lin YS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):398-403. PubMed ID: 23987486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.